penisdoc.md

← all papers · pharmacovigilance (6) Science journalism, not medical advice.

CML Drug Hits Developing Testes Hardest2026-05-14
Imatinib damages testes via c-KIT/PDGFR inhibition; neonatal exposure carries high irreversibility risk, adult exposure is more forgiving
A Scoping Review of Imatinib-Induced Testicular Toxicity and Male Fertility Impairment male infertility spermatogenesis scoping review pharmacovigilance pediatric urology
Pharma Authors Write Fictional Stories, Call It Evidence2026-04-02
Two of four authors work for Viatris — a PDE5i manufacturer — yet COI is listed as "not listed"
Narrative-Based Sexual Medicine: Clinical Vignettes and PDE5 Inhibitor Management in Real-World ED erectile dysfunction evidence quality pharmacovigilance
Your Antipsychotic Determines Which Sexual Side Effect You Get2026-03-07
Aripiprazole flagged for compulsive sexual behavior (ROR: 296.23); risperidone and paliperidone linked to decreased libido and anorgasmia — signals vary sharply by drug
Female Sexual Dysfunction Induced by Second-Generation Antipsychotic Drugs — A Disproportionality Analysis Based on the FAERS Database sexual dysfunction women's health antipsychotics pharmacovigilance
Which SSRI Hits Male Sexual Function Hardest?2026-02-07
Escitalopram and citalopram showed the strongest ED signals (ROR ~8) across 6.6 million FAERS reports; fluvoxamine's signal didn't reach significance
Male Sexual Dysfunction Associated with Selective Serotonin Reuptake Inhibitors (SSRIs): A Pharmacovigilance Disproportionality Analysis of FAERS Data antidepressants erectile dysfunction pharmacovigilance sexual dysfunction
Sildenafil Beats Tadalafil—But Read the Fine Print2025-11-19
Sildenafil scored higher than tadalafil on satisfaction and hardness in 132,100 real-world patients; vardenafil had the worst side-effect profile (47.4% vs ~34%).
Head-to-head Comparison of the Safety and Efficacy Profiles of Three Phosphodiesterase Type 5 Inhibitors through Patient-reported Outcomes of 130 000 Patients from a Direct-to-consumer Platform Database erectile dysfunction pharmacovigilance health services evidence quality
Venlafaxine Nearly Doubles Sexual Dysfunction Risk in Depressed Men2025-11-08
Venlafaxine raised sexual dysfunction risk 27% vs citalopram overall — and 93% higher among hospitalized depression patients
Sexual Dysfunction in Male Patients After Initiating Treatment with Antidepressants antidepressants sexual dysfunction pharmacovigilance cohort study